Atypical MOLes and Melanoma Early Detection Study (MoleMed)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

350 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-01

Study Completion Date

2023-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, ambispective, low-interventional clinical study evaluating molecular genetic markers for non-invasive differential diagnosis of benign and malignant pigmented skin and mucosal neoplasms. In retrospective cohorts genetics markers will be identified. In prospective cohort non-invasive adhesive system will be tested to identify malignant or benign lesions with prespecified sensitivity and specificity compared to other non-invasive techniques (i.e. dermoscopy) and using histopathological examination as a "golden standard".

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice

NCT05402059

Melanoma Melanoma (Skin) Melanoma, Uveal +5 more

UNKNOWN

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

NCT00040352

Melanoma Dysplastic Nevus Syndrome

RECRUITING

Risk Stratification Among Individuals Who Have Many Moles on Their Skin

NCT03080948

High-Risk Nevus Phenotype

COMPLETED

BioMEL- Diagnostic and Prognostic Factors in Melanoma.

NCT05446155

Melanoma Melanoma in Situ Dysplastic Nevi +3 more

RECRUITING

Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma

NCT01482260

Cutaneous Malignant Melanoma

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma Melanoma (Skin) Moles Nevus Nevus, Blue Nevus, Pigmented Nevus, Spitz Nevi, Spindle Cell Nevi, Dysplastic Dysplastic Nevus Syndrome Mucosal Melanoma Mucosal Melanosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Ambispective study with two retrospective cohorts and one prospective cohort

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1 (retrospective)

Only data from medical records and formalin-fixed paraffin-embedded tissue blocks will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio

Group Type NO_INTERVENTION

No interventions assigned to this group

Cohort 2 (retrospective)

Only data from medical records, formalin-fixed paraffin-embedded tissue blocks and cytologic slides will be collected from patients in this cohort. Patients with skin or mucosal melanoma and dysplastic nevi which have been already excised are eligible. FFPE tissue blocks with MPATH-Dx Class 1-2 vs Class 3-5 will be collected in approximately 1:1 ratio

Group Type NO_INTERVENTION

No interventions assigned to this group

Cohort 3 (prospective)

Patients with pigmented lesions on the skin or mucosa who are referred for excisional biopsy will be offered to apply investigated non-invasive adhesive system on their lesion just before the excisional biopsy. After biopsy cytological slides and FFPE tissue blocks will be prepared. All three types of obtained samples will be investigated separately (adhesive patches, cytologic slides and FFPE tissue blocks) for genetic markers whereas cytologic slides and FFPE tissue blocks will be processed also routinely and regular cytologic and histopathologic report will be generated.

Group Type OTHER

Non-invasive adhesive system (patch)

Intervention Type PROCEDURE

The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-invasive adhesive system (patch)

The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Cohort 1 (retrospective):

* Histologically confirmed diagnosis of melanocytic neoplasm of the skin or mucous membranes (benign, malignant or with unclear potential);
* The presence of a paraffin block with a tumor suitable for molecular genetic analysis;
* Signed informed consent form for living patients (for deceased, signing of a consent form with legal representatives is not required);
* Patient's age is over 18 years for the period of inclusion in the study (at the time of signing the consent form for living patients or for the excision biopsy period for deceased patients);
* Known clinical data of the patient (gender, age, skin phototype), hereditary history, medical history and follow-up of treatment outcomes for at least 5 years

2\. Cohort 2 (retrospective):
* Histologically confirmed diagnosis of melanocytic neoplasm of the skin or mucous membranes (benign, malignant or with unclear potential);
* The presence of a paraffin block with a tumor suitable for molecular genetic analysis
* The presence of cytological preparations (at least 2 glasses) of the primary tumor with tumor material
* Signed informed consent form for living patients (for deceased, signing of a consent form with legal representatives is not required);
* Patient's age is over 18 years for the period of inclusion in the study (at the time of signing the consent form for living patients or for the excision biopsy period for deceased patients);
* A known medical history and follow-up of treatment outcomes for at least 6 months.

3\. Cohort 3 (prospective):
* Clinically (including any type of dermatoscopy or other non-invasive diagnostic methods) suspected diagnosis of malignant melanocytic neoplasm (or neoplasms) of the skin or mucous membranes (or lesion(s) with unclear malignant potential)
* The patient is scheduled to undergo an excision biopsy (or wide excision) of the neoplasm (s) of the skin or mucous membranes within 3 months from the date of inclusion in the study and the patient is able to tolerate this intervention;
* Signed Informed Consent Form

Exclusion Criteria

Cohort 1:

* Unknown histological diagnosis (no information on the melanocytic nature of the neoplasm)
* Unsuitable for analysis paraffin block with a tumor or its absence
* Unknown history or lack of traceability after diagnosis within 5 years
* For the period of inclusion in the study (signing an informed consent form for living patients or an excision biopsy for deceased patients), the patient's age is under 18 years

2\. Cohort 2:
* Unknown histological diagnosis (no information on the melanocytic nature of the neoplasm)
* Unsuitable for analysis paraffin block with a tumor or its absence
* Unsuitable for analysis cytological preparations/smears (or the absence of tumor cells in cytological preparations)
* Unknown history or lack of traceability after diagnosis within 6 months.
* For the period of inclusion in the study (signing an informed consent form for living patients or an excision biopsy for deceased patients), the patient's age is under 18 years

3\. Cohort 3 (prospective):
* The patient is NOT scheduled to undergo an excision biopsy (or wide excision) of the neoplasm (s) of the skin or mucous membranes in the next 3 months since inclusion in the study OR the patient is not able to tolerate this intervention;
* The available morphological or cytological confirmation of the nature of the neoplasm (s) (benign or malignant), which (s) is planned to be removed in the framework of this study,
* Ulcerated neoplasms;
* Contact bleeding neoplasms;
* Non-melanocytic neoplasms;
* Neoplasms with an area of more than 5 sq. cm
* Neoplasms located subcutaneously or in soft tissues and, according to clinical signs, not associated with the skin
* Known allergy to any component of the applied adhesive system;
* Inability of the patient to follow the study procedures (including contacting the researcher during the follow-up visits) or other reasons that, in the opinion of the principal investigator, may become an obstacle for the patient to participate in the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No